AMP-activated protein kinase and nitric oxide regulate the glucose sensitivity of ventromedial hypothalamic glucose-inhibited neurons

Beth Ann Murphy,1,2 Kurt A. Fakira,1 Zhentao Song,1 Annie Beuve,1 and Vanessa H. Routh1

1Department of Pharmacology and Physiology, New Jersey Medical School, Newark; and 2Department of Pharmacology, Merck Research Laboratories, Rahway, New Jersey

Submitted 20 March 2009; accepted in final form 28 June 2009

Murphy BA, Fakira KA, Song Z, Beuve A, Routh VH. AMP-activated protein kinase and nitric oxide regulate the glucose sensitivity of ventromedial hypothalamic glucose-inhibited neurons. Am J Physiol Cell Physiol 297:C750–C758, 2009. First published July 1, 2009; doi:10.1152/ajpcell.00127.2009.—The mechanisms by which glucose regulates the activity of glucose-inhibited (GI) neurons in the ventromedial hypothalamus (VMH) are largely unknown. We have previously shown that AMP-activated protein kinase (AMPK) increases nitric oxide (NO) production in VMH GI neurons. We hypothesized that AMPK-mediated NO signaling is required for depolarization of VMH GI neurons in response to decreased glucose. In support of our hypothesis, we show that neuronal nitric oxide synthase (nNOS) or the NO receptor soluble guanylyl cyclase (sGC) blocked depolarization of GI neurons to decreased glucose from 2.5 to 0.7 mM or to AMPK activation. Conversely, activation of sGC or the cell-permeable analog of cGMP, 8-bromoguanosine 3’5’-cyclic monophosphate (8-Br-cGMP), enhanced the response of GI neurons to decreased glucose, suggesting that stimulation of NO-sGC-cGMP signaling by AMPK is required for glucose sensitivity in GI neurons. Interestingly, the AMPK inhibitor compound C completely blocked the effect of sGC activation or 8-Br-cGMP, and 8-Br-cGMP increased VMH AMPKα2 phosphorylation. These data suggest that NO, in turn, amplifies AMPK activation in GI neurons. Finally, inhibition of the cystic fibrosis transmembrane regulator (CFTR) Cl– conductance blocked depolarization of GI neurons to decreased glucose or AMPK activation, whereas decreased glucose, AMPK activation, and 8-Br-cGMP increased VMH CFTR phosphorylation. We conclude that decreased glucose triggers the following sequence of events leading to depolarization in VMH GI neurons: AMPK activation, nNOS phosphorylation, NO production, and stimulation of sGC-cGMP signaling, which amplifies AMPK activation and leads to closure of the CFTR.

THE VENTROMEDIAL HYPOTHALAMUS (VMH), which contains the arcuate and ventromedial (VMN) nuclei, is critical for regulating energy and glucose homeostasis (22). Within the VMH, specialized glucose-sensing neurons change their electrical activity in response to changes in extracellular glucose concentration (16, 24, 28). Glucose-excited (GE) neurons increase, whereas glucose-inhibited (GI) neurons decrease, their action potential frequency as glucose levels rise (23). Like the pancreatic β-cell, the ATP-sensitive K+ channel mediates glucose sensing in VMH GE neurons (23, 28). Less is known about the ion channel involved in glucose sensing by GI neurons; however, our previous data suggest that glucose inhibits VMH GI neurons via the activation of the cystic fibrosis transmembrane regulator (CFTR) Cl– conductance (9, 23).

The cellular fuel sensor 5’-AMP-activated protein kinase (AMPK) confers glucose sensitivity to VMH GI neurons (5, 16, 18). Fuel deficit increases the AMP-to-ATP ratio and activates AMPK (13). Depolarization of VMH GI neurons by decreased glucose is mimicked by the AMPK activator 5-aminomimidazole-4-carboxamide-1β-d-ribofuranoside (AICAR) and blocked by the AMPK inhibitor compound C (5, 16, 18). Moreover, AMPK activation mediates the fasting-induced increase in the response of VMH GI neurons to decreased glucose (18). Thus the level of AMPK activation is a critical determinant of glucose sensitivity in VMH GI neurons. However, the downstream signaling pathway by which AMPK regulates glucose sensing in GI neurons is unclear.

It is well established that AMPK inhibits the CFTR in a variety of cells (11, 26). This is consistent with our observations that decreased glucose depolarizes GI neurons by inhibiting a Cl– channel. This Cl– channel is likely to be the CFTR (9). Decreased glucose and AMPK activation also increase the production of the gaseous neurotransmitter nitric oxide (NO) by neuronal NO synthase (nNOS) in VMH GI neurons (5). Cultured VMH neurons from hyperglycemic rats neither increased NO production nor depolarize in response to decreased glucose. AMPK activation restored NO production in these neurons (4). These data suggest that NO may mediate the effects of AMPK in VMH GI neurons. Many of the effects of NO are mediated by activation of the NO receptor soluble guanylyl cyclase (sGC) and the production of guanosine 3’5’-cyclic monophosphate (cGMP) (3, 12). An elegant study by Lira et al. (14) demonstrated that activation of the NO-sGC-cGMP pathway caused an amplification of AMPK activity that was necessary for AMPK-mediated changes in glucose transporter GLUT4 expression in skeletal muscle cells. Thus the present study tests the hypothesis that a similar interaction between AMPK and NO via the sGC-cGMP signaling pathway is required for inhibition of the CFTR and depolarization of VMH GI neurons in response to decreased glucose. This hypothesis was tested using cultured VMH neurons stained with membrane potential-sensitive dye, electrophysiological recordings of GI neurons in brain slices, and VMH immunoblots for phosphorylated AMPKα2, nNOS, and CFTR.

MATERIALS AND METHODS

Animals

Male, 4- to 6-wk-old C57BL/6 mice (Taconic Laboratories, Germantown, NY) or Sprague-Dawley rats (Charles River) were housed in a temperature- and humidity-controlled facility with a 12:12-h light-dark cycle (lights on 0700–1900). Animals were weaned at 21 days of age and tested at 4–6 wk of age. Standard rodent chow
Preparation of Cultured Neurons

On the day of the experiment, C57/B6J mice were anesthetized with pentobarbital sodium (100 mg/kg) and then transecturally perfused with ice-cold oxygenated (95% O2-5% CO2) perfusion solution composed of the following (in mM): 2.5 KCl, 1.25 Na2HPO4, 5 MgCl2, 0.5 CaCl2, 28 NaHCO3, 7 glucose, 1 ascorbate, and 3 pyruvate, pH 7.4, with osmolarity adjusted to ~300 mosmol/kgH2O. Brains were removed and placed in slushy perfusion solution, and coronal hypothalamic sections (250–350 μm) containing the VMH were cut using a Vibratome (Vibratome Series 1000 cutting system, St. Louis, MO). Hypothalamic sections were maintained at 34°C in oxygenated artificial cerebrospinal fluid (aCSF) containing 5 mM glucose (in mM: 127 NaCl, 1.9 KCl, 1.2 KH2PO4, 26 NaHCO3, 1.3 MgCl2, and 2.4 CaCl2, pH 7.4, with osmolarity adjusted to ~300 mosmol/kgH2O with sucrose) for 30 min. Slices were transferred to normal oxygenated room temperature aCSF (2.5 mM glucose) for an additional 30 min before dissociation.

As described previously (28), brain slices were placed in Hibernate A/B27 medium containing 2.5 mM glucose (Brainbits, Carlsbad, CA). The VMH was dissected and digested in Hibernate A with papain (final concentration 20 U/ml) for 30 min in a 37°C rotating platform water bath rotating at 100 rpm. The tissue was then rinsed with Hibernate A/B27 and subjected to gentle trituration. After trituration, the cell suspension was centrifuged and the pellet resuspended in Hibernate A/B27 medium containing 2.5 mM glucose (Brainbits, Carlsbad, CA). Neurons were plated in growth medium with Fluoresbrite beads and incubated in glucose levels seen in the brain of fed (2.5 mM) or fasted (0.7 mM) rats (7, 25, 26). The beads were used for later data normalization.

Measurement of Membrane Depolarization Using Fluorometric Imaging Plate Reader Membrane Potential Dye

Neurons were visualized on an Olympus BX61WI microscope with a ×10 objective equipped with a red filter for fluorometric imaging plate reader membrane potential dye (FLIPR-MPD) visualization (excitation, 548 nm; emission, 610–675 nm). FLIPR-MPD (Molecular Devices, Sunnyvale, CA) was prepared according to the manufacturer’s instructions. Incubation of VMH neurons in 1.75% FLIPR-MPD at 37°C in extracellular solution (composition in mM: 135 NaCl, 5 KCl, 1 CaCl2, 1 MgCl2, 10 HEPES, and 2.5 glucose, pH 7.4) began 30 min before and continued throughout the duration of all experiments. Previous work showed that this concentration of FLIPR-MPD produced detectable fluorescence without causing toxicity (18).

Images were captured at 1-min intervals over the course of each experiment using a charge-coupled device camera (Cool Snap HQ; Photometrics). Images were acquired and analyzed using MetaMorph software (Universal Imaging). The fluorescence intensity of each image (expressed as gray scale units per pixel) was normalized to that of the coincubated fluorescent beads. Images were captured both before and after the extracellular test conditions were changed. In experiments evaluating the effects of test compounds on the response to decreased glucose, the initial extracellular recording (or bath) solution containing 2.5 mM glucose was exchanged 5 min after initiation of image acquisition with an identical solution containing 0.7 mM glucose. In these experiments, the test compound was present in both the 2.5 and 0.7 mM glucose-containing solutions. For single compound experiments, VMH cultures were preexposed for 30 min in the specific test compound. For agonist-antagonist studies, neuronal cultures were first incubated with the antagonist [7-nitroindazole (7-NINA), 1H-(1,2,4)oxadiazolo(4,3-c)quinoxalin (ODQ), or compound C] followed by 30 min in a combination of antagonist and agonist [7-NINA/AICAR; ODQ/AICAR, CC5-(1-phenylmethyl)-H-indazol-3-yl]-2-furanmethanol (YC-1), ODQ/YC-1]. In experiments evaluating the effect of a given compound on the membrane potential of VMH GI neurons in the absence of changing glucose, the test compound was added to extracellular solution containing 2.5 mM glucose 5 min after initiation of image acquisition. Test compounds then remained in the extracellular fluid throughout the imaging procedure.

As described previously, an average percent change of >11% in FLIPR-MPD fluorescence intensity between 10 and 20 min post-glucose change [%ΔFLIPR-MPD (10–20)] defined a depolarized neuron (18). Cell viability was confirmed at the end of each experiment by a 5-min exposure to 200 μM glutamate; neurons were considered to be viable if glutamate exposure increased FLIPR-MPD fluorescence intensity by at least 20%. Only glutamate-responsive neurons were used. The percentage of depolarized neurons [%ΔFLIPR-MPD (10–20) >11%] per culture dish was recorded for each treatment.

Electrophysiological Recording

Brain slices containing the VMH were prepared from Sprague-Dawley rats (Charles River) as described for Preparation of cultured neurons. Slices (300 μm) were maintained in oxygenated aCSF. Viable neurons were visualized and studied under infrared differential-interference contrast microscopy with a Leica DMLMS microscope equipped with a ×40 long-working-distance water-immersion objective. Current-clamp recordings (standard whole cell recording configuration) from neurons in the VMH were performed using a MultiClamp 700A (Axon Instruments, Foster City, CA) and analyzed using pCLAMP 9 software. During recording, brain slices were perfused at 10 μl/min with normal oxygenated aCSF. Borosilicate pipettes (1–3 MΩ; Sutter Instruments, Novato, CA) were filled with an intracellular solution containing (in mM) 128 K-glucuronate, 10 KCl, 4 KOH, 10 HEPES, 4 MgCl2, 0.5 CaCl2, 5 EGTA, and 2 Na2ATP, pH 7.2. Osmolarity was adjusted to 290–300 mosmol/kgH2O with sucrose.
crose. Input resistance (IR) was calculated from the change in membrane potential in response to small 500-ms hyperpolarizing pulses (~20 pA) given every 3 s. Junction potential between the bath and the patch pipette was nulled before the formation of a gigaohm seal. Membrane potential and action potential frequency were allowed to stabilize for 10–15 min after the formation of a gigaohm seal. Neurons whose access resistance exceeded 20 MΩ were rejected. The value was compared with controls measured immediately before treatment. Extracellular glucose levels were altered and chemicals added as indicated.

CFTR Immunoprecipitation and Western Blot Analysis for Phosphorylated and Total nNOS, AMPK, and CFTR

CFTR immunoprecipitation. VMH samples were lysed at 0°C in lysis buffer (150 mM NaCl, 0.02% sodium azide, 10 mM HEPES, 50 mM NaF, 0.1% SDS, 0.5% deoxycholic acid, 1% Nonidet P-40, 0.2 mM PMSF, 2 µg/ml pepstatin A, 2 µg/ml leupeptin, and 2 µg/ml aprotenin). Membrane fractions of whole cell lysates were obtained via repeated freeze-thaw cycles in liquid nitrogen and at 37°C. Lysates were precleared with Pansorbin 10% (Calbiochem, San Diego, CA), diluted in 1× RIPA buffer, and incubated with a polyclonal antibody against CFTR (1 µg/200 µl; Santa Cruz Biotechnology) or IgG (Jackson ImmunoResearch) for 12 h at 4°C, followed by pulldown with protein A/G Plus-agarose beads (Santa Cruz Biotechnology) for 2 h at 4°C under constant agitation. Eluted protein is subjected to immunoblot analysis as stated below.

Immunoblotting of phosphorylated AMPK, nNOS, and CFTR. VMH lysate as prepared above or immunoprecipitated lysate samples were electrophoresed and transferred to nitrocellulose membranes. Immunodetection with the following primary antibodies was performed for 12 h at 4°C: anti-nNOS (1:1,000; Millipore), anti-phospho-nNOS (1:1,000; Abcam, Cambridge, MA), anti-phospho-AMPKα (Thr172, 1:1,000; Cell Signaling, Danvers, MA), anti-AMPKα2 (1:1,000; Abcam), and anti-CFTR (1:1,000; Cell Signaling). CFTR phosphorylation was determined using the serine/threonine OmniPHOS kit (1:1,000; Millipore). Visualization was performed using relevant secondary antibodies (Jackson ImmunoResearch) and the SuperSignal Pico ECL kit (Thermo) and was quantified using Scion Image. Results are presented as percentages of control after normalization to glial fibrillary acidic protein (GFAP) or total nNOS, AMPK, or CFTR where applicable.

Chemicals

The AMPK activator AICAR (0.5 mM; Toronto Research Chemicals, Toronto, ON, Canada) and the cGMP analog 8-bromoguanosine 3,5'-cyclic monophosphate (8-Br-cGMP; 2 mM; Tocris, Ellisville, MO) were prepared in extracellular solution. The AMPK inhibitor compound C (10 µM; Calbiochem), the NOS inhibitors 7-NINA (10 µM; Tocris) and Nω-monomethyl-l-arginine (l-NMMA; 0.1 mM; Sigma, St. Louis, MO), the guanylyl cyclase inhibitor ODQ (10 µM; Tocris), the guanylyl cyclase activator YC-1 (10 µM; Cayman Chemicals; Ann Arbor, MI), or the CFTR channel modulator gemfibrozil.
Fig. 3. Percentage of depolarized neurons in VMH cultures from mice. AICAR increased whereas ODQ did not change the percentage of depolarized VMH neurons observed in 2.5 mM glucose. Decreasing glucose from 2.5 to 0.7 mM increased the percentage of depolarized VMH neurons. AICAR significantly increased the percentage of depolarized VMH neurons observed in response to decreased glucose. ODQ inhibited the effect of decreasing glucose on VMH neuron depolarization in the presence and absence of AICAR. Data are means ± SE and show the percentage of GI neurons per culture dish. The number of dishes used and number of cells analyzed are shown in parentheses above each bar (no. of dishes, no. of cells). Each dish comprised cells pooled from at least 3 mice. a,b,c,d = P < 0.01, bars with different letters represent values statistically different from each other.

Fig. 4. Percentage of depolarized neurons in VMH cultures from mice. 5-(1-(Phenylmethyl)-H-indazol-3-yl)-2-furanmethanol (YC-1) significantly increased the percentage of depolarized VMH neurons, whereas compound C (Cmpd C) had no effect in 2.5 mM glucose. YC-1 significantly increased the percentage of depolarized VMH neurons observed when glucose was reduced from 2.5 to 0.7 mM. Cmpd C reversed the effect of reduced glucose on VMH neurons in 2.5 mM glucose as well as when glucose was decreased from 2.5 to 0.7 mM in the presence and absence of YC-1 (18). The experimental manipulations in the current study are based on these previous results. The effects of the nNOS inhibitor 7-NINA on the number of VMH neurons that increased their FLIPR-MPD fluorescence in response to decreased glucose from 2.5 to 0.7 mM or AICAR are shown in Fig. 1. As we showed previously (18), AICAR increased the percentage of GI neurons observed in 2.5 mM glucose to that observed when glucose was lowered from 2.5 to 0.7 mM. A further increase in the percentage of GI neurons was observed when AICAR was combined with decreased glucose from 2.5 to 0.7 mM. 7-NINA alone did not change the number of GI neurons detected in 2.5 mM glucose (P > 0.05). However, 7-NINA reduced the number of VMH GI neurons detected as glucose was reduced from 2.5 to 0.7 mM in the presence and absence of AICAR to background levels (Fig. 1; P < 0.05).

Immunoblots of VMH tissue using a specific mouse phospho-nNOS antibody showed that both decreasing glucose from 2.5 to 0.7 mM or the presence of AICAR in 2.5 mM glucose

Statistics

Data were analyzed using one-way ANOVA followed by a Newman-Keuls post hoc test or a Student’s t-test, with P < 0.05 considered to be statistically significant.

RESULTS

nNOS is Required for Depolarization of GI Neurons in Response to Decreased Glucose and AMPK Activation

We have previously shown that a decrease in extracellular glucose concentration from 2.5 to 0.7 mM was the threshold glucose decrease required for detection of GI neurons using %ΔFLIPR-MPD (10–20) as an index of depolarization (18). An increase in the percentage of detectable GI neurons in response to this glucose decrease indicated increased responsiveness to decreased glucose, and conversely, a decrease in the percentage of GI neurons indicated impaired detection of decreased glucose. The maximal number of GI neurons was detected in response to decreased glucose from 2.5 to 0.5 mM or when glucose was decreased from 2.5 to 0.7 mM in the presence of AICAR (18). The experimental manipulations in the current study are based on these previous results. The effects of the nNOS inhibitor 7-NINA on the number of VMH neurons that increased their FLIPR-MPD fluorescence in response to decreased glucose from 2.5 to 0.7 mM or AICAR are shown in Fig. 1. As we showed previously (18), AICAR increased the percentage of GI neurons observed in 2.5 mM glucose to that observed when glucose was lowered from 2.5 to 0.7 mM. A further increase in the percentage of GI neurons was observed when AICAR was combined with decreased glucose from 2.5 to 0.7 mM. 7-NINA alone did not change the number of GI neurons detected in 2.5 mM glucose (P > 0.05). However, 7-NINA reduced the number of VMH GI neurons detected as glucose was reduced from 2.5 to 0.7 mM in the presence and absence of AICAR to background levels (Fig. 1; P < 0.05).

Immunoblots of VMH tissue using a specific mouse phospho-nNOS antibody showed that both decreasing glucose from 2.5 to 0.7 mM or the presence of AICAR in 2.5 mM glucose

Fig. 5. Percentage of depolarized neurons in VMH cultures from mice. 8-Bromoguanosine 3',5'-cyclic monophosphate (8-Br-cGMP) significantly increased the percentage of depolarized VMH neurons in 2.5 mM glucose as well as when glucose was reduced from 2.5 to 0.7 mM. This was completely blocked by Cmpd C. Data are means ± SE and show the percentage of GI neurons per culture dish. The number of dishes used and number of cells analyzed are shown in parentheses above each bar (no. of dishes, no. of cells). Each dish comprised cells pooled from at least 3 mice. a,b,c = P < 0.01, bars with different letters represent values statistically different from each other.
nonspecific NOS inhibitor L-NMMA (0.1 mM) blocked depolarization of VMH GI neurons (9, 23–25). Figure 2 shows that the gold standard method for evaluation of the glucose sensitivity was patch-clamp recordings of VMH GI neurons in brain slices, the above treatments. GFAP levels (data not shown) were unaffected by any of the treatments. A Total nNOS (Fig. 2A) and phosphorylation were measured using densitometry and quantitated relative to GFAP levels. AICAR was coapplied with compound C to confirm that increases in nNOS phosphorylation were mediated specifically via AMPK activation. Compound C reversed the increase in nNOS phosphorylation seen in the presence of AICAR (Fig. 2A; P < 0.01). Compound C blocked the effect of decreasing glucose on the depolarization of GI neurons in the presence and absence of YC-1 (P < 0.01).

We next confirmed our results using FLIPR-MPD with patch-clamp recordings of VMH GI neurons in brain slices, the gold standard method for evaluation of the glucose sensitivity of VMH GI neurons (9, 23–25). Figure 2B shows that the nonspecific NOS inhibitor L-NMMA (0.1 mM) blocked depolarization and increased action potential frequency of a GI neuron in response to decreased glucose. Furthermore, the increase in input resistance in response to decreased glucose from 2.5 to 0.1 mM was reduced from 28 ± 5 to 7 ± 3% in the presence of 0.1 mM L-NMMA (P < 0.01; Fig. 2C). The addition of the cell-permeable cGMP analog 8-Br-cGMP (2 mM) in 2.5 mM glucose significantly increased the number of depolarized GI neurons (Fig. 5; P < 0.01). The number of depolarized GI neurons observed when 8-Br-cGMP was added to 2.5 mM glucose was the same in the presence and absence of ODQ (+ODQ: 19 ± 3%, 7 dishes, 310 cells; −ODQ: 15 ± 4%, 5 dishes, 240 cells, P > 0.05), confirming that ODQ was acting via sGC inhibition. Finally, immunoblots of VMH tissue showed that both YC-1 and 8-Br-cGMP increased AMPK α2-subunit phosphorylation (Fig. 6; P < 0.01).

The number of GI neurons detected in VMH cultures as glucose was decreased from 2.5 to 0.7 mM was reduced in the presence of the sGC inhibitor ODQ (Fig. 3; P < 0.05). ODQ (10 μM) did not change the number of GI neurons detected in 2.5 mM glucose (Fig. 3; P > 0.05). Moreover, ODQ blocked depolarization of GI neurons in response to decreased glucose in the presence of AICAR (Fig. 3; P < 0.01).

In contrast to the sGC inhibitor ODQ, incubating VMH neurons with the sGC activator YC-1 (10 μM) increased the percentage of depolarized VMH neurons in 2.5 mM glucose (Fig. 4; P < 0.001). Furthermore, reducing glucose in the presence of YC-1 significantly increased the number of detectable GI neurons compared with reducing glucose alone (Fig. 4; P < 0.01). Compound C blocked the effect of reduced glucose on the depolarization of GI neurons in the presence and absence of YC-1 (P < 0.01).

The addition of the cell-permeable cGMP analog 8-Br-cGMP (2 mM) in 2.5 mM glucose significantly increased the number of depolarized GI neurons (Fig. 5; P < 0.01). Moreover, reducing glucose in the presence of 8-Br-cGMP significantly increased the number of depolarized GI neurons above that seen with 8-Br-cGMP or decreased glucose alone (Fig. 5; P < 0.01). Compound C blocked the effect of decreasing glucose in the presence of 8-Br-cGMP (Fig. 5; P < 0.01). The number of depolarized GI neurons observed when 8-Br-cGMP was added to 2.5 mM glucose was the same in the presence and absence of ODQ (+ODQ: 19 ± 3%, 7 dishes, 310 cells; −ODQ: 15 ± 4%, 5 dishes, 240 cells, P > 0.05), confirming that ODQ was acting via sGC inhibition. Finally, immunoblots of VMH tissue showed that both YC-1 and 8-Br-cGMP increased AMPK α2-subunit phosphorylation (Fig. 6; P < 0.01).
**CFTR Cl\(^-\) Conductance is a Downstream Target of AMPK-NO Signaling in VMH GI Neurons**

Gemfibrozil binds specifically to the CFTR (27). Using patch-clamp recordings, we previously have shown that gemfibrozil prevents Cl\(^-\) channel closure in response to decreased glucose (9). In the present study, we show that gemfibrozil blocked the effect of decreased glucose from 2.5 to 0.5 mM in the presence and absence of AICAR (Fig. 7; \(P < 0.01\)). Gemfibrozil did not change the percentage of depolarized VMH neurons in 2.5 mM glucose (Fig. 7). The maximal glucose decrease used in the present study illustrates that gemfibrozil completely blocks detection of all VMH GI neurons.

Immunoblots of VMH tissue show that decreased glucose increases CFTR phosphorylation (Fig. 8A; \(P < 0.001\)). AMPK inhibition with compound C inhibited the effect of decreased glucose on CFTR phosphorylation (Fig. 8A; \(P < 0.01\)). In contrast, AICAR in 2.5 mM glucose increased CFTR phosphorylation (Fig. 8A; \(P < 0.01\)). 8-Br-cGMP also increases CFTR phosphorylation in VMH tissue, and this was blocked by compound C (Fig. 8B; \(P < 0.001\)). Neither decreasing glucose nor 8-Br-cGMP affected the level of total CFTR (Fig. 8, A and B). Finally, nNOS inhibition with 7-NINA significantly inhibited CFTR phosphorylation in response to decreased glucose (Fig. 8C; \(P < 0.01\)). 7-NINA did not affect the level of total CFTR.

**DISCUSSION**

This study suggests that NO production and activation of the sGC-cGMP signaling pathway by AMPK, in turn, increases AMPK activity. This NO-sGC-cGMP-mediated amplification of AMPK activity is required for depolarization of VMH GI neurons.
neurons in response to decreased glucose. Furthermore, our data support our hypothesis that GI neurons depolarize as a result of closure of the CFTR Cl− conductance. We (18) recently showed that the response of VMH GI neurons to decreased glucose is enhanced after fasting. In contrast, the response of VMH GI neurons to decreased glucose is reduced under conditions where central hypoglycemia detection is impaired (15, 25). Thus VMH GI neurons may play a key role in the detection of energy deficit (e.g., fasting, hypoglycemia) and initiation of compensatory mechanisms. The signaling cascade mediating the interaction between AMPK and NO is a possible therapeutic target for restoring normal glucose sensitivity to GI neurons under conditions where it is impaired (e.g., following recurrent insulin-hypoglycemia).

These studies were based on the work of Lira et al. (14) in skeletal muscle cells as well as our own studies (5) implicating AMPK and NO in glucose sensing in VMH GI neurons. Our previous studies (5) showed that AMPK phosphorylates nNOS and increases NO production in VMH GI neurons in response to decreased glucose. AMPK also phosphorylates and activates nNOS in skeletal muscle (6). Lira et al. (14) then showed that the NO donor S-nitroso-N-penicillamine (SNAP) increases GLUT4 mRNA expression and that AMPK inhibition blocked this effect. These data point to an amplification of AMPK activity by NO in skeletal muscle cells. We hypothesized that a similar interaction occurred in VMH GI neurons. The data from the present study strongly support this hypothesis.

First, we have extended our earlier findings by showing that nNOS activation by AMPK is required for depolarization of VMH GI neurons in response to decreased glucose. This conclusion is strengthened by the consistency between data obtained from patch-clamp recordings of VMH GI neurons in brain slices, membrane potential dye imaging in cultured VMH neurons, and immunoblots of VMH tissue. Such consistency in results is important due to the limitations of each technique. Patch-clamp recording of VMH GI neurons directly monitors the changes in electrical activity and cellular resistance. The fact that the cells remain “in situ,” at least with respect to their immediate interactions with adjacent cells, is also a plus. However, it is always possible that these interactions influence the results. A benefit of the membrane potential dye imaging technique is that we are able to screen much larger populations of neurons than with electrophysiology. On the other hand, we have thus far been unable to measure a concentration-response relationship using this technique. Therefore, we must quantify our responses as the number of cells responding. The current data are consistent with our previous work (18) showing that the number of depolarized (GI) neurons in response to a maximal stimulus does not change and lend confidence to the results. Finally, immunoblots of VMH tissue verify the cellular target of the various pharmacological agents. However, single-cell resolution is not possible. Thus, although there are limitations of each technique used in the present study, the results taken together provide strong support for our hypotheses.

Our data also show that the sGC-cGMP signaling pathway mediates the effect of NO on GI neurons. Both the sGC activator YC-1 and the cGMP analog 8-Br-cGMP depolarize GI neurons and enhance their response to decreased glucose. On the other hand, inhibition of sGC with ODQ blocks depolarization of GI neurons in response to decreased glucose or AICAR. Thus decreased glucose activates AMPK, which then increases NO production via nNOS activation. NO binds to its receptor, sGC, leading to cGMP production. cGMP ultimately leads to closure of the CFTR Cl− conductance and depolarization in VMH GI neurons.

The effects of YC-1 and 8-Br-cGMP on depolarization of GI neurons in response to decreased glucose are completely blocked by the AMPK inhibitor compound C. Moreover, YC-1 and 8-Br-cGMP increase VMH AMPKα2 phosphorylation. Because YC-1 and 8-Br-cGMP also act downstream of AMPK and nNOS, these data clearly suggest that, as Lira et al. (14) found in skeletal muscle, the NO-sGC-cGMP pathway also increases AMPK activation in response to decreased glucose in VMH GI neurons. This amplification of AMPK by NO signaling may explain the exponential relationship between glucose concentration change and neuronal excitability of GI neurons we found using patch-clamp recordings (24). Similar signaling pathways in both skeletal muscle and GI neurons suggest that other signaling pathways used by skeletal muscle also may be applicable in GI neurons.

The question then arises as to how the NO-sGC-cGMP pathway regulates AMPK activity and apparently primes this enzyme to respond to energy deficit. It is well established that phosphorylation by upstream kinases [e.g., LKB-1 or calmodulin-dependent protein kinase kinase (CaMKKβ)] is necessary for AMPK activation in skeletal muscle and neurons (13, 30). Moreover, our observation that nNOS inhibition blocks the effect of AMPK activation with AICAR suggests that cGMP activates an upstream kinase of AMPK. This is consistent with Lira et al. (14), who found that nNOS inhibition blocked AICAR-induced GLUT4 translocation in skeletal muscle. A recent study by Zhang et al. (31) clearly demonstrated that NO-induced AMPK phosphorylation in endothelial cells results in AMPK activation. AMPK activation phosphorylates nNOS and increases the level of AMPK activation. This amplification of AMPK activity inactivates the CFTR Cl− conductance. Closure of this Cl− conductance causes depolarization of GI neurons and leads to neurotransmitter release. GK, glucokinase.
AMPK and NO Regulate Glucose Sensing by GI Neurons

C757

required CAMKKβ. Thus we speculate that NO-sGC-cGMP signaling activates CAMKKβ in VMH GI neurons.

It is important to note that in addition to the sGC-cGMP signaling pathway, NO also can activate AMPK through its effects on intracellular ATP levels and the generation of reactive oxygen species. For instance, NO reduces intracellular ATP levels through inhibition of creatinine kinase (10) and cytochrome c oxidase (7). However, AICAR activation of AMPK (13), as well as NO production (14) and depolarization of VMH-GI neurons (5), is independent of changes in intracellular energy status. Thus the requirement of nNOS activity for AICAR-induced GI neuronal depolarization argues that although NO may reduce intracellular ATP levels, a more direct effect of NO on AMPK also exists. Finally, NO production also causes the formation of reactive oxygen species such as peroxynitrite (ONOO−). ONOO− can activate AMPK independently of changes in cellular ATP levels (32). Hence, we cannot rule out this alternative mechanism for NO to activate AMPK in these studies.

For many years we have known that decreased glucose inactivated a Cl− conductance to depolarize GI neurons; however, the identity of this Cl− conductance remained elusive (23, 24). We hypothesized that the CFTR Cl− conductance might play a role in glucose sensing in GI neurons, because it is the only metabolically sensitive Cl− conductance described in the literature (29). Furthermore, our recent electrophysiological data showing that gemfibrozil prevented inactivation of a Cl− conductance in GI neurons in response to decreased glucose supported this hypothesis (9). Our current data showing that gemfibrozil prevents depolarization of VMH GI neurons in response to decreased glucose or AICAR provide much stronger support that the CFTR Cl− conductance is the final target of AMPK activation in VMH GI neurons leading to depolarization.

Our data are consistent with studies showing that AMPK inactivates the CFTR in other tissues (11, 26). However, it must be noted that gemfibrozil has nonspecific effects. Gemfibrozil belongs to the family of clofibric acid analogs that are used to lower triglycerides (1). The mechanism underlying this effect is unclear but is unlikely to involve CFTR; that is, gemfibrozil inhibits hepatic palmitoyl CoA hydrolase (20) and activates both hepatic and cortical peroxisome proliferator and activator receptor-α (PPARα) (21). Moreover, although clofibratic acid analogs do bind CFTR, they can either open or close the channel depending on enantiomer and tissue type (8). Our electrophysiological data indicating that the effects of gemfibrozil reverse at the Cl− equilibrium potential (9) and the literature suggesting that CFTR is the only Cl− channel associated with gemfibrozil (27) support our conclusions regarding the CFTR. Moreover, we have now shown that decreased glucose, AICAR, and 8-Br-cGMP phosphorylate the CFTR. The effects of decreased glucose and 8-Br-cGMP are blocked by nNOS and AMPK inhibition, respectively, further strengthening our conclusions. Finally, it has been shown that cGMP has AMPK-independent effects on the CFTR; however, these studies indicate that cGMP activates CFTR (2). Direct activation of CFTR by cGMP is not consistent with our results. Thus the most likely explanation for our results is that the sGC-cGMP pathway inhibits the CFTR via AMPK activation, although clearly further studies involving techniques such as small interfering RNA are needed to define the role of the CFTR in glucose sensing.

In summary, these data in combination with our previous findings provide strong evidence for the signal transduction pathway by which glucose regulates the activity of VMH GI neurons (Fig. 9); that is, decreased glucose activates AMPK. AMPK activation phosphorylates nNOS and increases NO production. NO binds to its receptor, sGC, and leads to cGMP production. cGMP increases the level of AMPK activation, possibly through an upstream kinase, and causes inactivation of the CFTR Cl− conductance. Closure of this Cl− conductance causes depolarization of GI neurons. We (9, 18) and others (17) have shown that GI neurons make up a significant percentage (~40%) of the population of neuropeptide Y (NPY) neurons in the arcuate nucleus. Moreover, the response of NPY-GI neurons to decreased glucose is enhanced following a fast (18). Conversely, the response of VMH GI neurons to decreased glucose is impaired under conditions where the ability of the brain to detect hypoglycemia is impaired (15, 25). Therefore, maintaining appropriate glucose sensitivity in VMH GI (and/or NPY-GI) neurons may be critical for the brain to detect and compensate for energy and/or glucose deficit. The AMPK-NO-AMPK signaling pathway is a putative therapeutic target for normalizing the glucose sensitivity of GI neurons under pathological conditions.

GRANTS

This work was funded in part by National Institutes of Health Grants 2RO1 DK55619 (to V. H. Routh) and R21 HL089771 (to A. Beuve) and Juvenile Diabetes Research Foundation Research Award 1-2007-13 (to V. H. Routh).

REFERENCES

AMP AND NO REGULATE GLUCOSE SENSING BY GI NEURONS


